GSK sues XenoPort to put Horizant breach on case to rest
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has sued its partner XenoPort in federal court in Delaware, where it is seeking a declaratory judgment that it has fulfilled its contractual obligations pertaining to the US marketing of the restless legs syndrome drug Horizant (gabapentin encarbil) extended release tablets. At the same time, XenoPort has filed its own complaint in a state court.